An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma - Concepedia

Concepedia

Publication | Closed Access

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

111

Citations

30

References

2015

Year

Bastian von Tresckow, Franck Morschhauser, Vincent Ribrag, Max S. Topp, Caly Chien, Shobha Seetharam, Regina Aquino, Sonja Kotoulek, Carla J. de Boer, Andreas Engert

Clinical Cancer Research

Abstract

JNJ-40346527, a selective inhibitor of CSF-1R was well tolerated, and preliminary antitumor results suggested limited activity in monotherapy for the treatment of cHL.

References

	Year	Citations

Page 1